Journal
CANCER LETTERS
Volume 367, Issue 2, Pages 89-92Publisher
ELSEVIER IRELAND LTD
DOI: 10.1016/j.canlet.2015.06.025
Keywords
Docetaxel; Polyploidy; Recurrence; Chemoresistance; Centrosome declustering
Categories
Funding
- National Cancer Institute [3R01CA169127-03S1]
- Georgia State University Molecular Basis of Disease Area of Focus graduate fellowship
Ask authors/readers for more resources
Although docetaxel significantly improves survival in a variety of malignancies, its clinical utility is severely restricted by acquired chemoresistance and disease relapse. To uncover the mechanisms underlying these all too common occurrences, an abundance of research has focused on mutations and gene expression patterns; however, these findings are yet to translate into improved outcomes for patients being administered this drug. These analyses have overlooked a promising lead in the quest to discern key mediators of resistance and relapse following docetaxel therapy: polyploidization. This process is manifested following docetaxel-mediated mitotic arrest by the appearance of giant, multinucleated cells, which slipped from mitosis without undergoing cytokinesis. Polyploid cells generally possess supernumerary centrosomes, are chromosomally instable, and resist chemotherapy. We thus suspect that chemoresistance and relapse following treatment with docetaxel might be combated by co-administration of centrosome declustering drugs, which could selectively destroy polyploid cells given that normal cells do not possess amplified centrosomes, an intriguing paradigm that warrants further investigation. (C) 2015 Elsevier Ireland Ltd. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available